The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 114 results:
Author Title Type [ Year(Asc)]
Filters: Author is Doumas, Michael  [Clear All Filters]
2018
Stavropoulos, K., Imprialos K. P., Athyros V. G., & Doumas M. (2018).  Renal resistive index for renovascular hypertension: In the quest of the Holy Grail.. J Clin Hypertens (Greenwich). 20(3), 589-591.
Doumas, M., Stavropoulos K., Imprialos K. P., Athyros V. G., & Karagiannis A. (2018).  Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. J Clin Hypertens (Greenwich). 20(4), 634-636.
Stavropoulos, K., Imprialos K. P., & Doumas M. (2018).  Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension.. J Clin Hypertens (Greenwich). 20(1), 65-68.
Stavropoulos, K., Imprialos K. P., Stavropoulos N., Bouloukou S., Kerpiniotis G., Dimitriadis K., et al. (2018).  Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease.. Cardiovasc Hematol Disord Drug Targets. 18(2), 120-126.
Imprialos, K. P., Stavropoulos K., & Doumas M. (2018).  Sodium-glucose Co-transporters 2 Inhibitors: The Miraculous Route from Hypoglycemic to Cardiovascular Drugs.. Cardiovasc Hematol Disord Drug Targets. 18(2), 83-85.
Stavropoulos, K., Imprialos K. P., Doumas M., Athyros V. G., & Karagiannis A. (2018).  Subclinical target organ damage in primary aldosteronism: resistant to spironolactone therapy?. J Hypertens. 36(3), 701.
Stavropoulos, K., Imprialos K., Doumas M., & Athyros V. G. (2018).  What is the role of statins in the elderly population?. Expert Rev Clin Pharmacol. 11(4), 329-331.
2017
Stavropoulos, K., Imprialos K. P., & Doumas M. (2017).  Abnormal blood pressure dipping in diabetic kidney disease: A black-race nightmare?. J Clin Hypertens (Greenwich). 19(12), 1336-1338.
Doumas, M., Stavropoulos K. V., Boutari C., Imprialos K. P., & Karagiannis A. (2017).  Blood pressure and cardiovascular outcomes: a closer look.. Lancet. 389(10076), 1295-1296.
Papademetriou, V., Nylen E. S., Doumas M., Probstfield J., Mann J. F. E., Gilbert R. E., et al. (2017).  Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study.. Am J Med. 130(12), 1465.e27-1465.e39.
Bress, A. P., King J. B., Kreider K. E., Beddhu S., Simmons D. L., Cheung A. K., et al. (2017).  Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial.. Diabetes Care.
Athyros, V. G., Tziomalos K., Doumas M., Sfikas G., & Karagiannis A. (2017).  The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins.. Curr Pharm Des. 23(10), 1477-1483.
Vogiatzakis, N., Tsioufis C., Georgiopoulos G., Thomopoulos C., Dimitriadis K., Kasiakogias A., et al. (2017).  Effect of renal sympathetic denervation on short-term blood pressure variability in resistant hypertension: a meta-analysis.. J Hypertens. 35(9), 1750-1757.
Imprialos, K. P., Stavropoulos K., Doumas M., Karagiannis A., & Athyros V. G. (2017).  The effect of SGLT2 inhibitors on cardiovascular events and renal function.. Expert Rev Clin Pharmacol. 10(11), 1251-1261.
Papademetriou, V., Lovato L., Tsioufis C., Cushman W., Applegate W. B., Mottle A., et al. (2017).  Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study.. Am J Nephrol. 45(2), 136-145.
Narayan, P., Doumas M., Kumar A., Faselis C. J., Myers J. N., Pittaras A., et al. (2017).  Impact of Cardiorespiratory Fitness on Mortality in Black Male Veterans With Resistant Systemic Hypertension.. Am J Cardiol. 120(9), 1568-1571.
Lovic, D., Narayan P., Pittaras A., Faselis C., Doumas M., & Kokkinos P. (2017).  Left ventricular hypertrophy in athletes and hypertensive patients.. J Clin Hypertens (Greenwich). 19(4), 413-417.
Imprialos, K. P., Stavropoulos K., & Doumas M. (2017).  Liraglutide and Renal Outcomes in Type 2 Diabetes.. N Engl J Med. 377(22), 2196.
Faselis, C., Boutari C., Doumas M., Imprialos K., Stavropoulos K., & Kokkinos P. (2017).  Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun.. Curr Pharm Des. 23(10), 1540-1550.
Doumas, M., Stavropoulos K., & Imprialos K. (2017).  Obstructive sleep apnea, hypertension, and fibrin clot properties: a novel pathogenetic link with cardiovascular disease?. J Hypertens. 35(5), 950-952.
Imprialos, K. P., Stavropoulos K., & Doumas M. (2017).  Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.. N Engl J Med. 377(25), 2502.
Raman, V. K., Tsioufis C., Doumas M., & Papademetriou V. (2017).  Renal Denervation Therapy for Drug-Resistant Hypertension: Does It Still Work?. Curr Treat Options Cardiovasc Med. 19(5), 39.
Imprialos, K., Faselis C., Boutari C., Stavropoulos K., Athyros V., Karagiannis A., et al. (2017).  SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature.. Curr Pharm Des. 23(10), 1510-1521.
Imprialos, K. P., Boutari C., Stavropoulos K., Doumas M., & Karagiannis A. I. (2017).  Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. J Neurol Neurosurg Psychiatry. 88(3), 249-253.
Stavropoulos, K., Imprialos K. P., & Doumas M. (2017).  Testosterone Replacement Therapy and Cardiovascular Risk-A Closer Look at Additional Parameters.. JAMA Intern Med. 177(9), 1393.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.